ClinicalTrials.gg
Active, not recruitingNCT05650879HER2Updated Jul 15, 2025

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

A Phase 1 interventional study of ELVN-002 and Fam-Trastuzumab Deruxtecan-Nxki in HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer and HER2 Gene Mutation, sponsored by Enliven Therapeutics. Active, not recruiting at 39 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Enliven Therapeutics · Phase 1, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
198
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain — 160 open to participants now, 333 under way, 112 of them phase 3. Carcinoma, Non-Small-Cell Lung · Spain.

Planned enrollment
390th of 797
198 · median 188
Started
2023
with 57 others
Phase 1
167 of 851
30 open now
Primary completion
2026-07
later than 82 of 332 live
Registered
645th of 851
by date

Among the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, this one is the 390th largest by planned enrollment of the 797 interventional ones that give a count, is one of 58 that started in 2023, is one of 167 in phase 1, reaches primary completion later than 82 of the 332 other live ones, and was the 645th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

160 of the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses. A second main question is to evaluate the concentration of ELVN-002 in the blood at different doses and to see how this correlates with safety and see how the concentration of drug changes over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-small cell lung cancer.

Read the detailed description

There are 4 parts to the trial. Part 1 is a dose escalation with ELVN-002 monotherapy for people with advanced stage solid tumors that have a HER2 mutation, amplification or high HER2 over-expression. Part 2 is an ELVN-002 monotherapy dose exploration where additional people may be enrolled at dose levels that have cleared the dose escalation in Part 1 to further evaluate the safety, tolerability, pharmacokinetics and clinical activity. Part 3 is a dose expansion of ELVN-002 monotherapy which will enroll up to 40 patients people with advanced stage HER2 mutant non-small cell lung cancer. Patients in Part 3 will be randomized 1:1 to receive one of two dose levels.

Part 4 is a combination dose escalation where, based on the results of Part 1 and 2, a combination of ELVN-002 and either fam-trastuzumab deruxtecan-nxki (in HER2 mutant non-small cell lung cancer) or trastuzumab emtansine (in HER2 positive breast cancer) will be evaluated for safety and tolerability.

03

Conditions studied

  • HER2 Mutant Non-small Cell Lung Cancer
  • HER2-positive Metastatic Breast Cancer
  • HER2 Gene Mutation
  • HER2 Amplification

Keywords

  • HER2 genetic alterations
  • HER2 mutation
  • ELVN-002
  • Non-small cell lung cancer
  • HER-2 positive metastatic breast cancer
  • Enhertu
  • trastuzumab emtansine
  • fam-trastuzumab deruxtecan-nxki
  • Kadcyla
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1a Monotherapy Dose Escalation and Exploration:

  • documented advanced stage solid tumor
  • Progressed following all standard treatment or not appropriate for standard treatment
  • mutation, HER2 amplification or HER2 positive based on local testing

Phase 1b Monotherapy

  • Pathologically documented unresectable and/or non-squamous NSCLC
  • HER2 mutation identified by tissue (fresh or archival) or ctDNA. Local testing for up to 20 patients the remainder centrally confirmed.
  • No known epidermal growth factor receptor (EGFR), ROS1, anaplastic lymphoma kinase (ALK), or BRAF V600E mutation
  • Progressed after receiving at least 1 prior systemic therapy including a platinum-based chemotherapy with or without immunotherapy, or not appropriate for standard treatment.
  • No prior HER2 tyrosine kinase inhibitor. Prior HER2 directed antibodies or anti-body drug conjugates are allowed
  • No limit on prior number of therapies

Phase 1a Combination with T-DXd

  • Pathologically documented advanced stage NSCLC
  • Progressed after receiving at least 1 prior systemic therapy.
  • HER2 mutation based on local/historical testing of tissue or circulating tumor DNA
  • No known EGFR, ROS1, ALK, or BRAF V600E mutation
  • No prior T-DXd
  • No clinically severe pulmonary compromise
  • No limit on prior number of therapies

Phase 1a Combination Breast Cancer

  • Documented HER2 positive (Immunohistochemical [IHC] 3+ or IHC2+/in situ hybridization (ISH+) breast cancer
  • Must have previously received trastuzumab, a taxane, and T-DXd (if available and appropriate) in the metastatic setting.
  • No limit on prior number of therapies
  • No prior T-DM1

All Phases

  • performance status of 0-1
  • ≥ 50%
  • count ≥ 100 x 109/L
  • ≥ 8.5 g/dL
  • ≥1.0 x 109/L
  • Total \< 1.5 times (ULN), except for patients with Gilbert's syndrome
  • (AST), alanine aminotransferase (ALT) \< 3 times ULN. In the setting of liver metastases \< 5 times ULN.
  • ≥ 60 mL/minute

Exclusion criteria

Exclusion Criteria All Phases:

  • Severe cardiac arrhythmias, requiring treatment, symptomatic congestive heart failure, myocardial infarction within 28 days prior to first dose, or unstable angina.
  • Another active within 2 years except basal cell skin cancer and carcinoma in situ treated curatively
  • Active or chronic liver disease
  • Active infection requiring systemic therapy within 14 days before the first dose
  • Brain lesion requiring immediate local therapy
  • Uncontrolled seizures
  • interval (QTc) of >470 milliseconds (ms) females or >450 ms for males by Fridericia (QTcF)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    Phase 1a Monotherapy Dose Escalation

    ELVN-002 will be administered either once or twice daily. Each cohort of patients will receive a higher dose. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.

    Drug: ELVN-002

  • Experimental
    Phase 1a Monotherapy Dose Exploration

    ELVN-002 will be administered either once or twice daily. A maximum of 80 patients will enroll in this arm. A maximum of 10 patients may be enrolled at a single dose or tumor type. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.

    Drug: ELVN-002

  • Experimental
    Phase 1b Monotherapy Dose Expansion

    ELVN-002 will be administered either once or twice daily. A maximum of 40 patients will enroll in this arm. Patients will be randomized 1:1 to one of two dose levels. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.

    Drug: ELVN-002

  • Experimental
    Phase 1a Combination Dose Escalation with T-DXd

    ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 5.4mg/kg of intravenous T-DXd once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.

    Drug: ELVN-002 · Drug: Fam-Trastuzumab Deruxtecan-Nxki

  • Experimental
    Phase 1a Combination Dose Escalation with T-DM1

    ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 3.6 mg/kg of intravenous T-DM1 once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.

    Drug: ELVN-002 · Drug: Trastuzumab emtansine

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities in Phase 1a monotherapy

    Time frame: 21 days

  2. Incidence of adverse events in Phase 1a monotherapy

    Time frame: 24 months

  3. incidence of laboratory abnormalities in Phase 1a monotherapy

    Time frame: 24 months

  4. incidence of ECG abnormalities in Phase 1a monotherapy

    Time frame: 24 months

  5. incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd)

    Time frame: 42 days

  6. Incidence of adverse events in Phase 1a combination with T-DXd

    Time frame: 24 months

  7. incidence of laboratory abnormalities in Phase 1a combination with T-DXd

    Time frame: 24 months

  8. incidence of ECG abnormalities in Phase 1a combination with T-DXd

    Time frame: 24 months

  9. incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1)

    Time frame: 42 days

  10. Incidence of adverse events in Phase 1a combination with T-DM1

    Time frame: 24 months

  11. incidence of laboratory abnormalities in Phase 1a combination with T-DM1

    Time frame: 24 months

  12. incidence of ECG abnormalities in Phase 1a combination with T-DM1

    Time frame: 24 months

  13. Incidence of adverse events in Phase 1b monotherapy

    Time frame: 24 months

  14. incidence of laboratory abnormalities in Phase 1b monotherapy

    Time frame: 24 months

  15. incidence of ECG abnormalities in Phase 1b monotherapy

    Time frame: 24 months

Secondary outcomes

  1. Objective Response rate in Phase 1a monotherapy

    For patients with measurable disease at baseline, confirmed response per RECIST 1.1

    Time frame: 24 months

  2. Objective response rate in Phase 1b monotherapy

    Confirmed response per RECIST 1.1

    Time frame: 24 months

  3. Duration of response in Phase 1b monotherapy

    The time from the first response to progression or death per RECIST 1.1

    Time frame: 24 months

  4. Brain metastases response in Phase 1b monotherapy

    for patients with measurable brain metastases at baseline, the percent of patients who have a confirmed response per RECIST 1.1

    Time frame: 24 months

  5. PK parameter of area under the curve of ELVN-002 in Phase 1a monotherapy

    the concentration of ELVN-002 measured in the blood over 24 hours at steady state

    Time frame: 21 days

  6. PK parameter of maximum concentration of ELVN-002 in Phase 1a monotherapy

    the maximum concentration of ELVN-002 measured in the blood at any time point at steady state

    Time frame: 21 days

  7. PK parameter of terminal half life of ELVN-002 in Phase 1a monotherapy

    the half life of ELVN-002 calculated from the concentration of ELVN-002 in blood

    Time frame: 21 days

  8. PK parameter of area under the curve of ELVN-002 in Phase 1b monotherapy

    the concentration of ELVN-002 measured in the blood over 24 hours at steady state

    Time frame: 21 days

  9. PK parameter of maximum concentration of ELVN-002 in Phase 1b monotherapy

    the maximum concentration of ELVN-002 measured in the blood at any time point at steady state

    Time frame: 21 days

  10. PK parameter of terminal half life of ELVN-002 in Phase 1b monotherapy

    the half life of ELVN-002 calculated from the concentration of ELVN-002 in blood

    Time frame: 21 days

07

Study locations

39 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jul 2026, 40 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 40 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Dec 14, 2022
StartActual
Mar 20, 2023
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05650879
Lead sponsor
Enliven Therapeutics
Responsible party
Sponsor
First posted
Dec 14, 2022
Start date
Mar 20, 2023
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jul 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion